RMG Wealth Management LLC Makes New $52,000 Investment in Boston Scientific Corporation $BSX

RMG Wealth Management LLC bought a new stake in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 500 shares of the medical equipment provider’s stock, valued at approximately $52,000.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC boosted its holdings in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. Miracle Mile Advisors LLC lifted its holdings in shares of Boston Scientific by 9.6% in the first quarter. Miracle Mile Advisors LLC now owns 6,025 shares of the medical equipment provider’s stock worth $608,000 after acquiring an additional 527 shares during the last quarter. OLD National Bancorp IN acquired a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $203,000. Capital Investment Advisors LLC grew its holdings in shares of Boston Scientific by 331.7% during the 1st quarter. Capital Investment Advisors LLC now owns 12,516 shares of the medical equipment provider’s stock valued at $1,263,000 after purchasing an additional 9,617 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in Boston Scientific by 9.1% in the 1st quarter. Farther Finance Advisors LLC now owns 12,062 shares of the medical equipment provider’s stock valued at $1,221,000 after purchasing an additional 1,002 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BSX shares. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a report on Saturday, September 27th. BTIG Research boosted their target price on shares of Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Finally, Leerink Partners raised their target price on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and a consensus price target of $120.71.

Insider Activity at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $17,972,457 over the last quarter. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 0.9%

Shares of Boston Scientific stock opened at $95.86 on Wednesday. The stock’s 50-day moving average is $102.53 and its 200 day moving average is $101.99. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The firm has a market cap of $142.05 billion, a price-to-earnings ratio of 57.06, a PEG ratio of 2.33 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company’s revenue was up 22.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.